Psittacosis future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
(Category)
m (Bot: Removing from Primary care)
 
Line 9: Line 9:
==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}


[[Category:Pulmonology]]
[[Category:Pulmonology]]
Line 15: Line 18:
[[Category:Infectious diseases]]
[[Category:Infectious diseases]]
[[Category:Disease]]
[[Category:Disease]]
 
[[Category:Emergency mdicine]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
[[Category:Emergency mdicine]]
[[Category:Disease]]
[[Category:Primary care]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]
[[Category:Pulmonology]]

Latest revision as of 23:51, 29 July 2020

Psittacosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Psittacosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Psittacosis future or investigational therapies On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Psittacosis future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Psittacosis future or investigational therapies

CDC on Psittacosis future or investigational therapies

Psittacosis future or investigational therapies in the news

Blogs on Psittacosis future or investigational therapies

Psittacosis

Risk calculators and risk factors for Psittacosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]

Overview

Future

  • Future challenges lay in the rigorous reporting of infections in both poultry and poultry workers and in the development of an avian and human vaccine.[1]
  • Use of ovotransferrin as anitmicrobial in poultry to reduce dissemination of bacteria into air. [2]

References

  1. Deschuyffeleer TP, Tyberghien LF, Dickx VL; et al. (2012). "Risk assessment and management of Chlamydia psittaci in poultry processing plants". Ann Occup Hyg. 56 (3): 340–9. doi:10.1093/annhyg/mer102. PMID 22302240. Unknown parameter |month= ignored (help)
  2. Van Droogenbroeck C, Dossche L, Wauman T; et al. (2011). "Use of ovotransferrin as an antimicrobial in turkeys naturally infected with Chlamydia psittaci, avian metapneumovirus and Ornithobacterium rhinotracheale". Vet. Microbiol. 153 (3–4): 257–63. doi:10.1016/j.vetmic.2011.05.016. PMID 21885218. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources